• Akeso entered a collaboration with Memorial Sloan Kettering to run a US Phase II trial of cadonilimab-based perioperative therapy in gastric cancer.
• Study targets locally advanced, resectable HER2-negative gastric or gastroesophageal junction adenocarcinoma; trial is actively enrolling across the US.
• Results are intended to support a future international, multicenter Phase III program for the cadonilimab combination regimen.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607140418PR_NEWS_USPR_____CN03977) on July 14, 2026, and is solely responsible for the information contained therein.